Management Team

  • Michaela Gertz

    Chief Financial Officer

    Shares: 21 000, 230 644 (warrants) MSc in Business and Economics, Uppsala University and Katholieke Universiteit Born: 1981

    Experience: Michaela Gertz most recently was CFO & Investor Relations Manager at PledPharma AB, a drug development company based in Stockholm. Ms. Gertz was instrumental in PledPharma’s IPO in 2011 and subsequent fund-raising efforts. Prior to that, Ms. Gertz spent three years as Head of Investor Relations and Financing at Accelerator Nordic AB. Before joining the life sciences industry, Ms. Gertz worked in finance and private equity at ITP Invest AB and Handelsbanken.

    Ongoing engagements:

    Past engagements during the last five (5) years:

    Erfarenhet: Michaela Gertz kommer senast från en tjänst som CFO & Investor Relations Manager på PledPharma AB, ett läkemedelsutvecklingsföretag baserat i Stockholm. Hon hade en viktig roll i PledPharmas börsnotering 2011, och har därefter bland annat genomfört flertalet kapitalanskaffningar. Dessförinnan var Michaela Gertz Head of Investor Relations & Financing på Accelerator Nordic AB under tre år. Innan hon började inom life science-branschen arbetade hon på riskkapitalbolaget ITP Invest AB samt på Handelsbanken Kapitalförvaltning.

    Pågående uppdrag:

    Avslutade uppdrag de senaste fem (5) åren:

  • Alex Karlsson-Parra

    Interim Chief Executive Officer

    Shares: 621 736 (private and through related persons’ holdings), 184 000 (warrants) M.D., Ph.D. Adjunct Professor in Clinical Immunology, Uppsala University, Sweden Born: 1950

    Experience: Alex Karlsson-Parra, MD, PhD has over 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical immunology. Dr. Karlsson-Parra was awarded the Athena Prize, the Swedish healthcare´s most prestigious award for clinical research, in 2014. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.

    Ongoing engagements:

    Past engagements during the last five (5) years: Board member of Immunicum.

    Erfarenhet: Över 20 års erfarenhet inom transplantationsimmunologi och tidigare ordförande för en svensk expertgrupp för klinisk immunologi. Tidigare chefsläkare på Fylkesjukhuset i Haugesund, Norge, och chefsläkare för klinisk immunologi för Sahlgrenska Universitetssjukhuset.

    Pågående uppdrag:

    Avslutade uppdrag de senaste fem (5) åren: Styrelseledamot i Immunicum.

  • Sharon Longhurst

    Head of CMC

    Shares: 8 493. 180 000 (warrants) Ph.D. in Virology, University of Warwick Born: 1969

    Experience: Sharon Longhurst has over 15 years in leading CMC efforts in small and medium sized organization. Sharon Longhurst joins Immunicum from her previous position as Senior CMC Manager at Akari Therapeutics, where she was responsible for all aspects of CMC, including clinical supply and distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC at Parexel Consulting. From 2005–2011, she was a Pharmaceutical Assessor at MHRA in London in the biologics/biotechnology unit and provided national and EU scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and gene therapy.

    Ongoing engagements:

    Past engagements during the last five (5) year:

    Erfarenhet: Sharon Longhurst har mer än 15 års erfarenhet av att leda CMC-arbete i både små och medelstora organisationer och kommer senast från Akari Therapeutics där hon var ansvarig för CMC. Dessförinnan var Sharon under fem år CMC-konsult vid Parexel Consulting. Mellan 2005 och 2011 var hon farmaciutredare vid enheten för biologi/bioteknik på MHRA i London, där hon arbetade med vetenskaplig rådgivning för Advance Therapy Medicinal Products (ATMPs), såväl nationellt som på EU-nivå, inom cell- och genterapi.

    Pågående uppdrag:

    Avslutade uppdrag de senaste fem (5) åren:

  • Margareth Jorvid

    Head of Regulatory and QA

    Shares: 19 418. 230 644 (warrants) MSc Pharm, Uppsala University, MSc MTRA, Cranfield University, MBA, Stockholm School of Economics Born: 1961

    Experience: Margareth Jorvid has over 30 years’ experience in Regulatory Affairs for pharmaceuticals and has worked at the Medical Products Agency (MPA), as well as in large and small pharmaceutical companies such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and quality assurance for pharmaceuticals and medical devices, as CEO of Methra Uppsala AB, LSM group. She is a Fellow and Honorary Life Member of TOPRA (The Organisation for Professionals in Regulatory Affairs), board member and TOPRA President 2005-2006.

    Ongoing engagements:

    Past engagements during the last five (5) years:

    Erfarenhet: Margareth Jorvid har över 30 års erfarenhet av Regulatory Affairs inom läkemedelsindustrin och har arbetat på Läkemedelsverket (MPA) samt stora och små läkemedelsföretag, som till exempel Roussel Nordiska, Hoechst Marion Roussel (Stockholm och Paris, Frankrike) och Neopharma. Sedan 2006 är hon även konsult inom regulatory affairs och kvalitetssäkring för läkemedel och medicintekniska produkter genom sitt företag Methra Uppsala AB, LSM group. Hon är medlem och hedersledamot i TOPRA (Organisation for Professionals in Regulatory Affairs), styrelseledamot och TOPRA president 2005-2006.

    Pågående uppdrag:

    Avslutade uppdrag de senaste fem (5) åren:

  • Sijme Zeilemaker

    Chief Operating Officer

    Shares: 13 302, 230 644 (warrants) MSc Biomedical Sciences, Leiden University Born: 1987

    Experience: Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted funding.

    Ongoing engagements:

    Past engagements during the last five (5) years:

    Erfarenhet: Sijme Zeilemaker var tidigare Director Business Development vid det prekliniska onkologibolaget InteRNA Technologies där han hade kontakt med läkemedels- och biotechbolag, skötte licensieringen av teknologin samt utvärderade möjligheterna till finansiering. Sijme har också varit affärschef vid 2-BBB Medicines och affärsutvecklingschef vid to-BBB Technologies där han bidrog till att stödja och initiera samarbeten med partner.

    Pågående uppdrag:

    Avslutade uppdrag de senaste fem (5) åren: